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Abstract 
Between 35% and 50% of patients with epilepsy are reported not to be fully adherent to their 
medication schedule. We aimed to conduct an economic evaluation of strategies for improving 
adherence to antiepileptic drugs.  Based on the findings of a systematic review, we identified an 
implementation-intention intervention (specifying when, where and how to act) which was tested in 
a trial that closely resembled current clinical management of patients with epilepsy, and which 
measured adherence with an objective and least biased method. Using patient-level data, trial 
patients were matched to those recruited to the Standard And New Antiepileptic Drugs trial, 
according to their clinical characteristics and adherence. Generalised linear models were used to 
adjust cost and utility in order to estimate the incremental cost per quality-adjusted life-year (QALY) 
gained from the perspective of the National Health Service in the UK. The mean cost of the 
intervention group, £1,340 (95% CI £1,132, £1,688) was marginally lower than that of the control 
group representing standard care £1,352 (95% CI £1,132, £1,727). QALYs in the intervention group 
were higher than the control, 0.75 (95% CI 0.70, 0.79), compared with 0.74 (95% CI 0.68, 0.79), 
ƌĞƐƵůƚŝŶŐŝŶĂĐŽƐƚƐĂǀŝŶŐŽĨ ? ? ? ? ? ? ? ?h^ ? ? ? ?ĂŶĚƚŚĞŝŶƚĞƌǀĞŶƚŝŽŶďĞŝŶŐĚŽŵŝŶĂŶƚ ?dŚĞƉƌŽďĂďŝůŝƚǇ
that the intervention is cost effective at a threshold of £20,000 per QALY is 94%. Our analysis lends 
support to the cost-effectiveness of a self-directed, implementation-intention intervention for 
improving adherence to antiepileptic drugs. However, as with any modeling dependent on limited 
data on efficacy, there is considerable uncertainty surrounding the clinical effectiveness of the 
intervention which would require a substantive trial for a more definitive conclusion.  
Key words 
Adherence, economic evaluation, cost-effectiveness analysis, antiepileptic drug
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Introduction 
Medication adherence is the extent to which patients take their medicines as prescribed, from 
initiation through to the end of prescribing, in terms of both prescribed dose and dosing interval [1].  
Between 35% and 50% of patients are reported not to be fully adherent to their antiepileptic drug 
(AED) dosing schedules [2,3,4].  These patients are exposed to a higher risk of seizures and an 
increased time to remission [4].  Low adherence to AEDs may also be associated with increased 
mortality including sudden unexplained death [5], and hospital admissions [6]. Whilst large cross-
sectional studies have demonstrated substantial difference in health outcomes between patients 
with high and low adherence, prospective studies are lacking. However, current evidence suggests 
that sub-optimal adherence can lead to reduced quality of life and increased pressure on healthcare 
budgets.  
The causes of non-adherence are multifactorial [7,8,9], and include those that are related to: (i) 
patients, such as forgetfulness, ambivalence or different beliefs and understanding of the aims of 
treatment; (ii) healthcare personnel, such as a lack of shared decision-making; (iii) health systems, 
such as barriers to accessing treatment or information; (iv) socioeconomics, including patientƐ ?
inability to pay for AEDs; (v) the condition, such as treatment discontinuation upon seizure control; 
and (vi) treatment, for instance, adverse effects, complexity or frequency of dosing regimen.  Non-
adherence is often categorised as being intentional or unintentional, with the former potentially 
ŝŶĨůƵĞŶĐĞĚďǇŝŶƚĞƌǀĞŶƚŝŽŶƐƐƵĐŚĂƐƵƐĞŽĨĞĨĨĞĐƚŝǀĞĐŽŵŵƵŶŝĐĂƚŝŽŶƚŽŝŵƉƌŽǀĞƉĂƚŝĞŶƚƐ ?ŵŽƚŝǀĂƚŝŽŶ ?
understanding or beliefs [10]. Unintentional non-adherence may be improved by interventions that 
remind patients when doses are to be taken or by the removing barriers to adherence such as with 
digital diary reminder alarms or by reducing the regimen frequency [11,12]. 
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A Cochrane review of trials of adherence-enhancing interventions for epilepsy [13] identified 
behavioural interventions, such as the use of intensive reminders (e.g. prescription refill and 
appointment-keeping reminders) [14], and  ?implementation intention ?interventions (where patients 
note when and where they intend to take their AEDs, and what they would be doing at the moment 
they will take their medications) [15], to provide more positive effects on adherence than 
interventions based on education and counselling.  However, trials were short in duration, were 
inadequately powered (or not designed) to detect differences in seizure control, and did not 
consider the cost-effectiveness of interventions. 
Given that interventions to improve adherence require utilisation of healthcare resources, and that 
the case for the cost-effectiveness of adherence-enhancing interventions in general has not been 
made [16,17], we aimed to estimate the cost-effectiveness of the most plausibly effective 
ŝŶƚĞƌǀĞŶƚŝŽŶĨŽƌŝŵƉƌŽǀŝŶŐƉĂƚŝĞŶƚƐ ?ĂĚŚĞƌĞŶĐĞƚŽƐ ? 
 
Methods 
Study selection 
The Cochrane review noted that the studies included differed widely according to intervention and 
measures of adherence and combining data in a meta-analysis was not deemed to be appropriate 
[13]. The review also highlighted methodological limitations increasing the risk of bias, and 
limitations in reporting that reduce transparency. Five studies were conducted in the United States 
[14,18-21] and one was conducted in the United Kingdom [15]. Four studies were pre-1990 [14,18-
20], and therefore may not adequately reflect current clinical practice, and one considered a sample 
of only 22 patients [21].   We focussed on the trial that measured adherence with an objective and 
least biased method and for which we were able to obtain patient-level data to improve the 
accuracy of the economic evaluation. 
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dŚŝƐƌĞƐƵůƚĞĚŝŶƚŚĞƐĞůĞĐƚŝŽŶŽĨĂƚƌŝĂů ?ŚĞƌĞĂĨƚĞƌƌĞĨĞƌƌĞĚƚŽĂƐƚŚĞ ?ƌŽǁŶ ?ƚƌŝĂů ? ? ? ? ?ǁŚŝĐŚ
demonstrated that a simple, intention-implementation intervention using self-administered 
questionnaire, improved adherence compared to control at 1-month (93.4% vs. 79.1% doses taken, 
p<0.01).  Eighty-one patients were recruited to the trial from the outpatient clinic at the Royal 
Hallamshire Hospital, Sheffield, United Kingdom.  Eligibility was based on a diagnosis of epilepsy, 
patients being aged 16 and over who were responsible for their own medicine taking. Only those 
who were prescribed AEDs which could be dispensed in a monitoring bottle were included. Patients 
were excluded if they were receiving a diagnosis of epilepsy for the first time, if they were already 
using an adherence-enhancing intervention, if they were taking AEDs more than twice a day or had 
learning difficulties [15]. 
Intervention 
The intervention was administered as part of a booklet of self-report measures, after a neurology 
appointment [15].  Both control and intervention groups completed the booklet, with the booklet 
for the intervention group containing an extra page corresponding to the intervention.  The 
intervention was designed to automate triggering intended behaviour (medicine taking), based on 
ĂŶ “ŝĨ-ƚŚĞŶ ?ĨŽƌŵĂƚ ? “If it is time X in place Y and I am doing Z, then /ǁŝůůƚĂŬĞŵǇƉŝůůĚŽƐĞ ? ?.   
Adherence measurement 
Patients were supplied their medication in bottles with a Medication Event Monitoring System 
device (MEMS, MWV Healthcare, Richmond, VA), designed to register the times at which the bottle 
was opened. Patients completed an additional questionnaire booklet one month after the initial visit 
to provide follow-up information, and returned their MEMS device. 
Economic evaluation 
We conducted a cost-utility analysis of the adherence-enhancing intervention for adult patients with 
epilepsy.  Direct medical costs were estimated from the perspective of the National Health Service in 
Comment [P1]: The intervention was 
the III questionnaire not the MEMS bottles. 
I think we should insert a picture with the 
III here (with permission we could use the 
same one we included in the original 
paper). We can also include a photo of the 
mems bottles. 
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the UK, and health outcomes expressed as quality-adjusted life-years (QALYs) in line with guidance 
issued by the National Institute for Health and Care Excellence (NICE) [22]. NICE is the statutory body 
in the UK responsible for providing national guidance and advice to improve health and social care.  
Core tenets to its decision-making are the consideration of clinical effectiveness and cost-
effectiveness, with the latter measured in terms of incremental costs per QALY gained.  A modelled 
extrapolation of trial data to 1 year was performed to reduce time horizon bias and assess the 
ŝŵƉĂĐƚŽĨƚŚĞŝŶƚĞƌǀĞŶƚŝŽŶ ?ƐĚƵƌĂďŝůŝƚǇŽŶĐŽƐƚ-effectiveness. 
Estimating impact of adherence on health outcomes 
The Brown trial measured adherence as the primary outcome but did not measure costs or health 
outcomes [15].  We therefore estimated the impact of the adherence-enhancing intervention on 
costs and utilities indirectly by matching patients to those recruited to the Standard And New 
Antiepileptic Drugs (SANAD) trial [23], for which we had access to patient-level data. Patients in the 
Brown trial were first matched with SANAD patients according to prescribed AED. In the case where 
more than one AED matched (e.g. in the context of combined treatment), the primary AED was 
assigned. In cases where no AED matched, the ǁĂƐĂƐƐŝŐŶĞĚĂƐ ?KƚŚĞƌ ?.  In the base-case 
analysis, patients were matched using propensity scoring, based on age, gender and 12-month 
remission. As the majority of patients who entered the SANAD trial were treatment naïve, patients 
from SANAD were matched based on year 1 characteristics to allow the inclusion of remission.  The 
number of missed doses calculated from MEMS data in the Brown trial was mapped onto responses 
to the adherence question in SANAD, which asked patients  “,ŽǁŽĨƚĞŶ ?in the past three months, 
would you say that you have missed taking your antiepileptic medication? ?ǁŝƚŚ ?ƉŽƐƐŝďůĞƌĞƐƉŽŶƐĞ
categories: never, <once a month, between once a week and once a month, and >once a week.  
Costs 
Comment [P2]: The reviewers have 
asked for more info on the measures. The 
only measure we cover here seems to be 
this. Perhaps Tony can add a little about 
how the questionnaire was administered, 
what else it asked about and how many 
items it included. 
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Healthcare resource use in the SANAD trial was measured by administering a questionnaire to 
patients at 1 year, which asked about their use of medications, attendance (or admission) to 
hospital, investigations received and appointments with health care professionals over a 3 month 
recall period. Resource use was scaled up to a period of 1 year and combined with AED cost, in line 
with the original trial-based economic analysis [23,24]. This implicitly captured any resources used to 
manage adverse reactions.  Total costs, based on NHS unit costs, were inflated to 2011 values [25].  
A Generalised Linear Model (GLM) (gamma family, log link) was used to adjust total cost for age, 
gender, remission status and AED. Observations were weighted in the GLM by the number of times 
they appeared as a nearest neighbour during propensity matching. 
The cost of the intervention was based on the time taken to discuss the intervention with the 
patient. Expert opinion indicated that the intervention would take 10 minutes of a health care 
ƉƌŽĨĞƐƐŝŽŶĂů ?ƐƚŝŵĞƚŽĞǆƉůĂŝŶĂŶd administer, and that a nurse was the most likely health care 
professional to administer the intervention.  The intervention cost therefore comprised of £17 staff 
costs [25], plus £0.67 for the cost of providing a single sheet of printed paper. The latter was based 
on £250 for a printer, conservatively assuming that GP surgeries are not equipped with printing 
facilities, £15 for a cartridge capable of printing 400 sheets, and £6.50 for the required quantity of 
paper.  
Utilities 
^EƉĂƚŝĞŶƚƐ ?ƌĞƐƉŽŶƐĞƐƚŽ the NEWQoL questionnaire at 1 year follow-up were converted to 
utilites by applying the tariffs for the NEWQoL-6D epilepsy-specific QALY measure [26]. The EQ-5D 
has been criticised previously for not reflecting the paroxysmal nature of seizures and epilepsy.  
Stavem (1998) [27] found little statistical association between the EQ-5D and health state utility 
measured directly by time trade off and standard gamble methods that more directly measure the 
impact of epilepsy on patient well-being. The NEWQoL-6D includes domains considered to be of 
more relevance to epilepsy, namely: worry, depression, memory, concentration, control and stigma. 
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QALYs were calculated according to the trapezoidal rule for the area under the curve, and adjusting 
for baseline. In order to calculate health state utilities for patients from the Brown trial, we specified 
a GLM for disutility = 1-utility, (Poisson family, log link), to adjust for age, gender, and baseline 
remission status and AED. Observations were weighted in the GLM by the number of times they 
appeared as a neighbour during propensity matching. 
Analysis 
Coefficients from regression models were applied to the matched subset of patients from the Brown 
trial, to estimate costs and utilities. Where AEDs from the Brown trial did not match with an AED 
from SANAD, a mean average of the AED GLM coefficients was used for modelling. No discounting of 
costs or health utility was applied as the time horizon of the model was set to one year.  Cost-
effectiveness was assessed according to the incremental cost effectiveness ratio (ICER) for the 
intervention, calculated as: 
 
An intervention with a lower ICER is deemed to be more cost effective than one with a higher ICER. 
NICE considers an ICER below £20,000 to £30,000 per QALY to mean a health technology represents 
good value for money for the NHS in the UK [22].  
Sensitivity analysis 
A univariate sensitivity analysis was conducted to assess the impact of varying the total cost of the 
intervention (£10 to £100 as a pragmatic, plausible range) on the ICER.  Sensitivity analyses based on 
the 95% confidence intervals of the GLM coefficients were also considered, however these would 
not make allowance for any correlation between coefficients and therefore a probabilistic sensitivity 
analysis (PSA), which assessed the simultaneous uncertainty of model parameters, was considered 
more informative. Correlation between GLM coefficients is reflected in the PSA by use of Cholesky 
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decomposition upon the covariance matrix. Uncertainty in the cost of the intervention was 
represented by a gamma ĚŝƐƚƌŝďƵƚŝŽŶŽŶƚŚĞŶƵŵďĞƌŽĨŵŝŶƵƚĞƐŽĨŶƵƌƐĞƐ ?ƚŝŵĞ ?ǁŝƚŚĂŶĂƐƐƵŵĞĚ
95%CI of (5, 15 minutes). PSA was accomplished by drawing iteratively (10,000 times) from the 
generated distributions.  A cost effectiveness acceptability curve (CEAC) was constructed to depict 
the probability of the intervention being cost-effective for a given cost-effectiveness threshold [28]. 
Scenario analyses  
The model was analysed with a healthcare professional cost of £27, to represent 10 minutes of the 
time of a consultant who might alternatively administer the intervention [25].  A further analysis 
calculated QALYs from UK tariffs applied to EQ-5D responses at 1 year follow-up. The assumption 
that the effect of the intervention would be maintained for the full year was tested in alternative 
scenarios, whereby i) adherence was assumed to reduce immediately to the level of the control 
group after 1 month (duration of the Brown trial); and ii) where the adherence benefit tapered in a 
linear manner, to that of the control group over a 3-month period. 
The effects of alternative approaches for matching were explored by firstly including AED in the 
propensity scoring, and secondly by implementing an exact distance method of matching patients 
according to their age (within 5 years), gender, 12-month remission and AED. 
The economic evaluation was analysed in Microsoft Excel 2010 and reported according to the 
Consolidated Health Economic Evaluation Reporting Standards [29]. 
 
Results 
Patients 
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In the base case, all 72 patients from the Brown trial were matched with 224 (of 739 patients for 
whom demographic and either cost or NEWQoL data were available) from SANAD. The baseline 
demographic and clinical characteristics are presented in Table 1. 
Inert Table 1 here 
The results of mapping of patients within each adherence category in the Brown trial to those in the 
SANAD trial are presented in Table 2. It is noted that SANAD participants have a higher percentage of 
patients who self-report to be 100% adherent. 
Insert Table 2 here 
Base case analysis 
The GLM coefficients for costs and disutilities are presented in Table 3. Patients in remission 
generate significantly lower costs than those whose seizures are uncontrolled. Treatment costs 
associated with females are lower than those associated with males, and costs increase with age. 
The base-case AED, carbamazepine, was the least expensive overall, followed by topiramate, 
oxcarbazepine, lamotrigine and then gabapentin.  The relationship between cost and adherence is 
not monotonic; highest costs are seen for the least adherent patients, followed by the most 
adherent patients, then those who miss at least one dose per month, but less than one dose per 
week. Patients who miss less than one dose per month are associated with the lowest cost. Patients 
in remission had higher utility than those experiencing uncontrolled seizures.  Utility appears lowest 
for carbamazepine, followed by lamotrigine, gabapentin, topiramate, then oxcarbazepine. Whilst 
patients who miss less than one dose per month, or at least one dose per month but less that one 
per week, have marginally higher utility than those who miss no doses, lowest adherence is 
associated with a negative effect on utility.  
The mean cost of the intervention group, £1,340 (95% CI £1,132, £1,688) is lower than that of the 
control group £1,352 (95% CI £1,132, £1,727) resulting in a cost saving of £12 (95% CI -£96, £61), or 
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£1,158 per 100 patients. QALYs in the intervention group were 0.75 (95% CI 0.70, 0.79) compared 
with 0.74 (95% CI 0.68, 0.79) in the control group, a difference of 0.01 (95% CI 0.00, 0.03). As the 
intervention is both less costly and more effective, it dominates the control strategy. 
Insert Table 3 here 
Sensitivity and scenario analyses 
A univariate sensitivity analysis of the cost of the intervention resulted in ICERs ranging from the 
intervention being dominant when the cost was £10, to £5,915 per QALY gained when the cost was 
£100. Cost effectiveness estimates were stable to univariate sensitivity analyses on the GLM 
coefficients. The PSA indicated that 56% of simulations were in the south-east quadrant of the cost-
effectiveness plane (dominant) while 37% of simulations suggested that the intervention was both 
more costly and more effective (Figure 1). Less than 6% of simulations showed the intervention to be 
less effective. The probabilities of the intervention being cost-effective at ceiling ratios of £20,000 
and £30,000 per QALY were 94% and 95%, respectively (Figure 2).  
Insert Figures 1 and 2 here 
In a scenario where the intervention is delivered by a consultant rather than a nurse, the 
intervention remains dominant, with a mean cost of £1,350. A scenario in which adherence in the 
intervention group tapers to that of control group between months 1 and 4 produces an ICER of 
£4,645 per QALY gained, while a scenario of the intervention having no effect on adherence after 1 
month increases the ICER to £15,281 per QALY gained. When EQ-5D was used as a utility measure, 
QALYs in the intervention group are 0.68 (95% CI 0.55, 0.75), compared to 0.66 (95% CI 0.52, 0.73) in 
the control group; the incremental QALY of 0.02 (95% CI -0.01, 0.05), indicating that the intervention 
dominates.  When AED was included in propensity score matching, the incremental cost of £338 
(95% CI £260, £424) and QALY of 0.03 (95% CI -0.01, 0.06) resulted in an ICER of £13,361 per QALY. 
The alternative method of matching by age, gender, remission and AED resulted in an incremental 
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cost of £125 (95% CI £-115, £306), a QALY gain of 0.02 (95% CI 0.01, 0.04) and an ICER of £5,121 per 
QALY gained. 
Discussion 
Our economic evaluation suggests that a simple intervention which encourages patients to make 
explicit their intentions to take their antiepileptic medications can represent a cost-effective use of 
NHS resources, being both less costly and more effective and a 95% probability of being cost 
effective.  Considering different modelling assumptions, the ICER remains well within the NICE 
threshold of £20,000 to £30,000 per QALY. 
The analysis revealed that the associations between adherence, and cost and health state utility are 
not monotonic, with the highest costs and lowest health state utility observed for the least, and then 
most adherent patients.  We hypothesise that patients who are most adherent to their medication 
may also engage more closely with the healthcare system in general; thus generating more visits to 
specialists and associated costs. Conversely, patients with poorly controlled tonic clonic seizures may 
be more adherent, but consume higher healthcare resources due to their refractory epilepsy. Least 
adherent patients may generate increased costs through increased seizure frequency, seizure 
severity and seizure-related injuries. Cross-sectional studies have indicated that low adherence is 
associated with lifestyle choices such as drinking and smoking, and is also more prevalent in patients 
with mental health problems and general poor health, these factors are not directly associated with 
epilepsy, but impact upon quality of life and resource use. We also note that perceived 
improvements in health, such as good seizure control can be a risk factor for non-adherence.  A 
prospective study would be required to further explore these potential confounding factors. 
This study is the first economic evaluation of any adherence-enhancing intervention in epilepsy, and 
has strengths in that it utilitises patient-level data from randomised controlled trials and addresses 
many of the methodological limitations of comparable evaluations in other clinical contexts [16,17]. 
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Our study ďĞŶĨŝƚƐĨƌŽŵŚĂǀŝŶŐƚŚĞŝŶƚĞƌǀĞŶƚŝŽŶ ?ƐĞĨĨŝĐĂĐǇĞƐƚĂďůŝƐŚĞĚƵƐŝŶŐĂŶŽďũĞĐƚŝǀĞĂŶĚƌĞůŝĂďůĞ
measure of adherence [30].  Cost and utility decrement models were generated as generalised linear 
models, accounting for relevant covariates and the positively skewed nature of the data [31]. 
Correlations among covariates were conserved for the probabilistic sensitivity analysis. 
Our analysis necessitated a number of important assumptions owing to the short follow up period 
and a lack of data on health outcomes and costs in the Brown trial.  Consequently, our reliance on 
matching patients to the SANAD trial resulted in near, but imperfectly matched populations. For 
instance, the majority of SANAD patients (82%) had only 1 year of treatment experience at the point 
of analysis, whilst the Brown trial focussed on chronic cases (mean of 19.5 years duration of 
seizures).  There is conflicting evidence as to whether duration of treatment experience has a 
negative impact on adherence (Cramer et al, 2002) or is a neutral factor (Sweileh et al, 2011; Ferrari 
et al, 2013).  There is also evidence that uncontrolled seizures is associated with non-adherence 
(Ferrari et al, 2013) though one study found erratic adherence with over consumption of AED was 
more prevalent (Carpentier, 2013) in refractory epilepsy.  We also acknowledge the differences in 
the methods of adherence measurement in the SANAD and Brown studies. Comparison between the 
two data sets suggests that a lower proportion of patients report low adherence when assessed by 
questionniare, in agreement with literature on the topic [32]. There is also very little evidence linking 
adherence to AEDs directly with seizure count [2], meaning that our analyses may be susceptible to 
bias; though recent seizure experience is linked to higher AED adherence (Ferrari et al, 2013).  This 
may have been further affected by our extrapolation of 1-month data to a period of a year. 
However, with respect to behavior modification, there is evidence of sustainable effects on 
outcomes with comparable interventions targeting smoking cessation [33], blood donation [34] and 
oral contraceptive use [35]. 
Notwithstanding these limitations, the results remained well within the cost-effectiveness threshold 
when uncertainty was explored in sensitivity analyses. Comparing best-worst scenarios the ICER 
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remained below £30,000 per QALY gained and probabilistic sensitivity analysis showed a very high 
probability of the intervention being cost-effective. 
Based on the results of our evaluation, our analysis lends support to the cost-effectiveness of a self-
directed, implementation- intention intervention (III) for improving adherence to antiepileptic drugs 
in the context of the NHS in the UK. The low cost of the intervention and likely ease of widespread 
implementation makes it an appealing method to improve health outcomes in epilepsy. However, as 
with any modeling dependent on limited data on efficacy, there is considerable uncertainty 
surrounding the clinical effectiveness of the intervention which would require a more substantive 
trial for a more definitive conclusion. What is more, the patients included in the Brown trial all had 
established epilepsy and were taking AEDs prior to the study. Whilst there is no psychological reason 
why an implementation intention intervention should not be effective when AEDs are first started 
(and indeed it may, theoretically, be more effective in this setting), future studies would have to 
examine the effects of an III in the first treatment scenario.  
In the past 20-30 years there has been a significant investment in the development of new 
medicines for epilespy. Whilst these new ƐŚĂǀĞŝŶĐƌĞĂƐĞĚƉƌĞƐĐƌŝďĞƌƐ ?ĐŚŽŝĐĞ ?ƚŚĞƌĞŝƐŶŽ
evidence that they have had any impact on the porportion of people with refractory epilepsy. Given 
the treatment gap in epilespsy as well as significant problems with adherence, it is important that 
there is adequate assessment of inverventions to improve adherence, which offer an opportunity to 
improve quality of life in a cost effective way. The Brown study has demonstrated the positive effect 
of an III on tablet taking behaviour in patients with epilepsy. This study suggests that the 
intervention may be cost-effective. An appropriately powered future study will need to demonstrate 
whether improved AED use is associated with improvements in health and social outcomes and 
patients ?ƋƵĂůŝƚǇŽĨůŝĨĞ ? 
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Figure legends: 
 
Figure 1. Plot of 10,000 probabilistic sensitivity analysis simulations on the cost effectiveness plane 
 
Figure 2. Cost-effectiveness acceptability curve for the base-case analysis 
 
